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Delivering siRNA or shRNA into the developing embryos is still a main challenge to use of RNAi in mammalian systems.
Here we analyze several factors inﬂuencing RNAi-mediated silencing of Sry gene, which is a tightly controlled spatiotemporal
expressed gene and only shortly expressed in developing mouse embryo gonad. A Sry gene-speciﬁc shRNAs expression vector
(pSilencer4.1/Sry565) was constructed. The shRNA constructs were mixed with polyethylenimines (PEIs) to form a complex and
then injected into pregnant mice though tail vein. Our results showed that Sry gene was downregulated signiﬁcantly in developing
embryos. Further study revealed that knocking-down of Sry expression resulted in feminization of gonad development in mouse
embryos and the expression level of Sox9 and Wt1 gene was also signiﬁcantly changed by downregulation of Sry.T h et r a n s f e c t i o n
eﬃciencyisassociatedwiththeamountofplasmidDNAinjection,injectiontime,injectionspeed,andvolume.Ourstudiessuggest
that transplacental RNAi could be implemented by tail vein injection of plasmid vector into pregnant mice.
1.Introduction
RNAi is a useful approach for discerning the role of genes
in particular cell, tissue, or organism and also has potential
applications in treatment of disease [1]. This evolutionary
conserved pathway can be programmed to inhibit the
expression of any genes by delivering small interfering RNA
(siRNA) with sequence that is complementary to the target
mRNA [2]. RNAi has been used extensively to probe gene
function in mammalian cells [3, 4]. However, in contrast to
the great success of RNAi in mammalian cell culture, there
have been many challenges for use of RNAi in animal in vivo
[5, 6], especially in developing embryos.
Delivery of siRNA to postimplantation-staged embryos
continues to be a major limitation in the widespread appli-
cation of this important technology. Information regarding
the prenatal delivery of plasmid DNA (pDNA) comes
largely from the gene therapy ﬁeld where in utero gene
targeting/therapy has been proposed as a method to treat
diseases that aﬀect the developing embryos [7], which may
ultimately be the most eﬀective mean to treat genetic defects.
Various routes of pDNA delivery have been attempted for
fetal “gene therapy” including direct injection of the fetus
[8, 9], injecting into the placenta or umbilical cord, and
injecting into the amniotic cavity or the yolk sac [10, 11].
To obtain eﬃcient results, precise techniques are needed for
all of these manipulations. Intravascular delivery of naked
DNAisincreasinglyrecognizedasapreferredroutetodeliver
nucleic acids to target tissues [12]. Because of its simplicity
and eﬀectiveness, high levels of transgene expression can be
achieved and sustained. The “tail vein injection” method had
been widely used before, to allow expression of a variety
of plasmids in the liver [13–15]; expression of a speciﬁc
gene by the DNA can be observed within the ﬁrst 24 hours
and approximately 50% of hepatocytes express the transgene
[13]. In recent years, tail vein injection has been employed2 Journal of Biomedicine and Biotechnology
to silence genes in neonatal [16] and adult mice [14], and
several previous studies have validated “tail vein injection”
method to deliver constitutively expressed short hairpin
(sh) RNAs to pregnant mice during the postimplantation
period of development, and knockdown of some speciﬁc
genes could be observed in developing embryos [17, 18].
However, little is known if the approach could be used in
silencing some spatiotemporal genes in developing embryos
in vivo.
Sry is essential for initiating male sex diﬀerentiation in
mammals [19, 20]. In mice embryos, Sry exhibits a tightly-
controlled and limited spatiotemporal proﬁle of expression
in the precursors of Sertoli cells of XY gonad [21, 22]. Thus,
Sry is likely to act as a trigger for a cascade of molecular
and cellular events that direct the bipotential gonad to dif-
ferentiate into a testis in a center-to-pole manner. Previous
studies revealed that Sry was ﬁrst detected in the genital
ridge at 10.5 days following coitum (dpc), shortly after the
emergence of the genital ridges in mouse. After reaching
peak levels of expression at 11.5dpc, Sry is rapidly declined
and extinguished shortly after 12.5dpc. Sry is activated in
a very short period in gonadal somatic cells, and it may
trigger testis-speciﬁc genes to initiate testis diﬀerentiation
[23, 24]. Numerous additional genes, including Sox9 [25–
28], Wt1 [29–32], Dax1 [33], Sf1 [34], and Gata4 [35, 36],
have been identiﬁed to be involved in this complex process.
H o w e v e r ,t h ed i r e c tt a r g e tg e n e so fSry in vivo havenot been
identiﬁed. Studies have shown that Sry expression level has
to reach a certain threshold to induce testis development
[37]. Insuﬃcient expression of Sry results in abnormal testis
development of XY embryos. In fetuses of XY Gata4/Fog2
null mutation mice, the Sry transcript levels are signiﬁcantly
reduced and result in abnormality in gonadgenesis [36].
XY sex reversal occurred when the Sry expression level
reduced to ∼25% of the wild type. However, since the Sry
gene is not been knockedout in developing embryos, the
genes which regulated by Sry in sex diﬀerentiation have
not yet been well documented. Further study is needed to
address if inhibition of Sry in developing mouse embryos
could result in sex reversal and abnormal embryo testis
development.
In the present study, tail vein injection approach was
employed to deliver the shRNA expression vector to knock-
down Sry expression in developing embryos, and certain
factors aﬀecting the silencing of the target gene were
investigated. Additionally, the development of male gonads
with Sry silence phenotype was also presented, and the
expression levels of several Sry-related sex determination
genes were analyzed.
2.MaterialsandMethods
2.1. Experimental Animal. All animal experiments were
performed in accordance with the International Guiding
Principles for Biomedical Research. ICR mice were obtained
from the Peking University Health Science Experimental
Animals Center (Beijing, China). Five-week-old female mice
were maintained and mated in a temperature and humidity
controlled room with food and water ad labium. Each female
mouse was injected with 5IU PMSG (Sigma, St. Louis, MO).
After 48h, 5IU HCG (Sigma, St. Louis, MO) was injected
intotheintraperitonealcavity,andthenpairedwithonemale
in the afternoon. Female mice with vaginal plugs were placed
in separate cages in the next morning. The gestation age was
deﬁned as day after coitum (dpc).
2.2. Construct of siRNA Expression Vectors. pSilencer4.1-
CMV/neo vector (Ambion, CA) was used to construct the
siRNA expression plasmids. For tracking the siRNA expres-
sion, we inserted an EGFP gene into the pSilencer4.1-
CMV/neo vector under the SV40 promoter to replace the
neomycin gene. The EGFP gene was ampliﬁed by PCR
using pEGFP-N3 (Clontech, CA) as template and then
inserted to the NruI site and BclIs i t e .T h eP C Rw a s
performed as the following condition: 94◦C for 30s, 60◦C
for 1min, and 72◦C for 1min, followed by 10min at 72◦C.
The primers for amplifying EGFP are as follows: EGFP-
F, 5 ACTGATCAATCGCCACCATGGTGAGCAAG3 , EGFP-
R, 5 AGATCGCGATTACTTGTACAGCTCGTCCA3 .G e n e -
speciﬁc shRNAs target to Sry were ligated downstream of
the CMV promoter. Our previous study has shown that
one of the Sry-speciﬁc shRNA that target 565 to 585 site
of Sry mRNA could signiﬁcantly knock-down Sry gene
expression [38]. The sequence of shRNA Sry 565–585 is
as follows: GAT CCG CAG CAG TTT C AT GAC CAC-
TTC AAG AGA GTG GTC ATG AA A CTG CTG CTT.
The forward and reverse synthetic oligonucleotides were
annealed and inserted into the Hind III and BamHI sites of
the pSilencer4.1-CMV/neo vector to construct the shRNA
expression vectors, pSilencer4.1/Sry565. Of note, pSilenc-
er41-CMV/neo is a circular plasmid encoding a hairpin
siRNA whose sequence is not found in the mouse, human,
or rat genome database and could be used as an ideal
negative control plasmid. A negative control vector, pSi-
lencer4.1/EGFP, was constructed in which Neomycin gene
was replaced by EGFP cassette on pSilencer4.1-CMV/neo.
The structure of shRNA expression vectors was shown in
(Figure 1(a)).
2.3. Plasmids and PEI Micelles Complex Formation. Sry
siRNA expression plasmid pSilencer4.1/Sry565 and nega-
tive control plasmid pSilencer4.1/EGFP were extracted by
endotoxins-free plasmid extraction kit (Omega) and dis-
solved in sterile and free of endotoxins water; DNA concen-
tration and quality was determined by spectrophotometer.
The linear polyethylenimine (PEI, ExGen500, Mw 22, 000)
was obtained from Fermentas (Canada). To synthesize the
pDNA-PEI conjugate, pSilencer4.1/Sry565 (from 0.2 to
2.0mg) or pSilencer4.1/EGFP (from 0.2 to 2.0mg) were
diluted in 0.1 to 1.0mL of sterile 5% glucose solution,
vortexing gently and spining down brieﬂy. Meantime, dilute
15mM of ExGen 500 to sterile 5% glucose solution (from
0.1mL to 1.0mL). Vortex gently and spin down brieﬂy.
Then add the diluted ExGen 500 to the diluted DNA
solution and vortex-mix the solution immediately. Twenty
minutes incubation at room temperature was needed for
pDNA/PEI micelles formation.Journal of Biomedicine and Biotechnology 3
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Figure 1: Schematic diagram of designing shRNAs expression vectors, and expression of siRNAs in embryos of pregnant mice. (a)
Construction of shRNA expression plasmids. pSilencer4.1-CMV/neo vector was used as basic plasmid to construct the siRNA expression,
plasmids pSilencer4.1/Sry565. The EGFP coding region was obtained from the pEGFP-N3 vector and cloned downstream of the SV40
promoter to replace the Neomycin gene to construct the plasmid. Gene-speciﬁc shRNAs (Sry565) or scrambled shRNA (not shown) were
then ligated downstream of the CMV promoter. (b) Tail vein injection. The shRNA expression plasmids were delivered into pregnant mice
though tail vein injection. (c) 11.5dpc embryos were dissected from the uterus, and deciduas and membranes were removed. Transmitted
light and ﬂuorescence images of embryos were recorded using a Nikon-inverted ﬂuorescence microscope to determine the extent of GFP
expression. The left embryo was injected with pSilencer4.1/Sry565. The right embryo was injected with 5% glucose solution. (d) Analysis of
EGFP expression in 11.5dpc embryos. Semiquantitative RT-PCR was used to detect the GFP expression in diﬀerent tissues, including liver,
muscle, gonad, and limbs, in the absence (−) or presence of (+) pSilencer4.1/Sry565.
2.4. Tail Vein Injection. Tail vein injection in mice was
performed as described by TE Gratsch et al. [17]w i t ha
little modiﬁcation. Brieﬂy, mice were warmed for 5min
using a heat lamp and a heating pad, and then siRNA
expressionplasmid(pSilencer4.1/Sry565)ornegativecontrol
plasmid (pSilencer4.1/EGFP) was mixed with or without
PEI micelles, injected into the tail vein of pregnant mice,
respectively.Toinvestigatetheeﬀectsofinjectiontime,speed,
and volume on the transfection eﬃciency, 0.2 to 2.0mL of
pDNA/PEI micelles were injected with the injection speed
range from 5 seconds to 30 seconds at 5.5dpc to 10.5dpc.
2.5.EmbryoCollectionandDissection. From11.5to15.5dpc,
pregnant female mice were sacriﬁced by cervical dislocation
and embryos were dissected immediately from the deciduas.
Embryos at 10.5dpc to 12.5dpc were more accurately staged
by counting the tail somites (ts) at the time of dissection
[27] .E m b r y o sw i t h1 2t s( ±2ts) were the equal of 10.5dpc,
and 20 ts (±2ts) were considered as 11.5dpc, and those
with 30ts (±3ts) were equivalent to 12.5dpc. Embryos with
14.5dpcand15.5dpcwerestagedbyexaminingforelimband
hindlimbmorphologies.EmbryosshowingGFPﬂuorescence
in the urogenital system were selected for further analysis.
Embryos were classiﬁed from weak to strong by GFP
expression level in the urogenital system varied. The sex of
embryos was genotypically identiﬁed by PCR as described
previously [39]. The gonad/mesonephros complex dissected
from each selected embryos were frozen in liquid nitrogen
immediately and used for RNA or protein extraction to
determine the expression level of Sry and GFP.
2.6. Real-Time RT-PCR. Sry and GFP transcript levels were
determined on single pair of gonad/mesonephros complex
obtained from individual fetuses using a quantitative RT-
PCR [40]. Brieﬂy, total RNA was isolated from each single
pair of gonad/mesonephros complex of male embryos using
the RNA easy mini kit (QIAGEN, CA), and then reverse
transcribed at 42◦Cf o r1hi na5 0μL reaction mixture using
the Moloney-Murine Leukaemia Virus Reverse Transcrip-
tase (M-MLV-RT, Promege, CA) and oligo-dT15 primer.
Quantitative RT-PCR was performed to detect the relative
amount of mRNAs, including Sox9, WT1 (−KTS), WT1
(+KTS), Amh, Dax1, Sf1,a n dGata4 as described previously
[31]. Sequences of the primers used for PCR ampliﬁcation4 Journal of Biomedicine and Biotechnology
Table 1: 11.5dpc Mouse embryos used to analysis of Sry knockdown. GFP expression was assessed macroscopically by examining whole
urogenital systems under a dissecting microscope equipped with ﬂuorescence optics. The density of GFP ﬂuorescence was classiﬁed as low,
medium, or high. Feminization was assessed by gonadal histology, immunoﬂuorescent marker expression, or quantitative RT–PCR.
Plasmid treated at the 9.5dpc Number of embryos at 11.5dpc
(both sexes)
Number of embryos (both sexes)
showing high GFP expression
Total number of feminized
males/males with high GFP
5% glucose solution n = 60 0 0/27
pSilencer4.1/EGFP n = 78 40 0/18
pSilencer4.1/Sry565 n = 320 56 8/27
Table 2: Primers used for real-time RT-PCR analysis.
Genes Primer name Primer sequences 5  →3 
Sry Sry-F AGCTCTTACACTTTAAGTTTTGAC
Sry-R GCAGCTCTACTCCAGTCTTGCC
Wt1(−KTS) Wt1(−KTS)-F TACCTTAAAGGGCCACGGTAT
Wt1(−KTS)-S GAAGGGCTTTTCACCTGTATGA
Wt1(+KTS) Wt1(+KTS)-F GCTGGGAGCTCCAGCTCAGT
Wt1(+KTS)-R GGGCTTTTCACTTGTTTTAC
Sox9 Sox9-F GGTGCTGAAGGGCTACGCTGGACG
Sox9-R GGCTGGTACTTGTAATCGGGTGGTC
Gata4 Gata4-F CGAGGGTGAGCCTGTATGTAA
Gata4-R TGGCCTGCGATGTCTGAGTG
Amh Amh-F TCCTACATCTGGCTGAAGTGATATGGGAGC
Amh-R CTCAGGGTGGCACCTTCTCTGCTTGGTTGA
Sf1 Sf1-F TGGTGTCCAGTGTCCACCCTTAT
Sf1-R TCCGTCACGTGTAATGCTTGT
Dax1 Dax1-F AGAGTATGCCTATCTGAAAGGGACCGTG
Dax1-R ACGACATCGCTATTGATGAATCTCAGCA
β-actin β-actin-F AACCCTAAGGCCAACCGTG
β-actin-R CAGGATTCCATACCCAAGAAGG
of the relevant target genes are listed in Table 2. All samples
were normalized against β-actin, using the comparative CT
method (ΔΔCT). For each primer, standard curves were
constructed to conﬁrm ampliﬁcation eﬃciency. Data was
expressed as relative normalized expression level, where the
value of gene expression in embryos treated with 5% glucose
solution was normalized to the β-actin expression level and
was deﬁned at 1.0.
2.7. Testes Histological Section. The male embryos were ﬁxed
in Serra (ethanol: 37% formaldehyde: acetic acid, 6:3:1)
for 24h, then embedded in paraﬃn, and sectioned to 7μm.
The embryo slices were stained with hematoxylin and eosin
followedstandardprocedureandanalyzedundermicroscope
with magniﬁed 200 times.
2.8. Statistics. Statistical analyses were performed using
software from SPSS for Windows 13.0 (SPSS Inc., IL). All
data was described as mean ± SEM. Student’s t-test was
performed to analyze the two-tailed P values. Diﬀerences
were considered signiﬁcant when P v a l u ei sl e s st h a n0 . 0 5 .
3. Results
As known, Sry is a tightly controlled and limited spatiotem-
poral expression gene, and its expression is ﬁrst detected
in the genital ridge at 10.5dpc and reaches peak levels
of expression at 11.5dpc, then the expression of Sry was
declined rapidly and extinguished at 12.5dpc.
shRNA expression vectors were delivered into more than
100 pregnant mice by tail vein injection at 6.5 to 9.5dpc. Our
results showed that ∼15% pregnant mice had abortion after
injecting shRNA plasmids. To check the eﬃciency of shRNA
transfection,apartofpregnantmice(n = 67)weresacriﬁced
at11.5dpc,andtotal320embryoswerecollected.Ourresults
revealed that the expression of GFP was found in the whole
embryos (Figures 1(c) and 1(d)) without preference for
tissue types (Figure 1(d)). These results suggested that tail
vein injection is a useful approach to deliver the shRNA into
the pregnant embryos.
In our next step, we tried to understand if the Sry expres-
sion was aﬀected by the shRNA; quantitative RT-PCR and
Western blotting analysis were performed to detect the SryJournal of Biomedicine and Biotechnology 5
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Figure 2: Quantitative RT-PCR and Western-blotting analysis to detect the expression of gonadal GFP and Sry expression in embryonic
mouse gonads. Gonads at 11.5dpc were grouped on the basis of overall GFP expression observed at the macroscopic level. Quantitative
RT-PCR was then carried out on grouped gonads. Gene expression was normalized to IL3 (autosomal in mouse) (mean ± SEM; n = 3). (a),
Relative expression of GFP in embryos. Relative high level of GFP expression was found in controls, and variable expression levels of GFP
in male and female gonads with Sry knockdown. (b) Sry expression in control and Sry knockeddown gonads. (c) Western-blotting analysis
of Sry expression. Control males which treated with 5% glucose solution or negative control vector (pSilencer4.1/EGFP), males embryos
treated with Sry shRNA (pSilencer4.1/Sry565) and with low, medium, or high GFP expression, and the control females treated with control
vector and show high GFP expression were all collected at 11.5dpc and each gonad were separated for protein isolation. Western-blotting
were performed to determine the SRY expression level in each group of embryos and β-actin was also be detected as a loading control. (d)
Quantitative analysis of the Sry protein level. The expression of Sry was determined by Western blot. The value of Sry protein expression
level was normalized to the β-actin expression level and the relative expression level of Sry in embryos which treated by 5% glucose solution
was set at 100%. Results are expressed as the mean ± SEM, (n>20).
level in certain embryos. The gonads were dissected from
selected embryos, and green ﬂuorescence was determined
using a microscopic. Gonads were then classiﬁed into groups
on the basis of their GFP expression level, which based at
the macroscopic level: low, medium, or high. Quantitative
PCR with reverse transcription (RT-PCR) analysis revealed
aninversecorrelationbetweengonadalGFP andendogenous
Sry gene expression; Gonads with high levels of GFP showed
signiﬁcantly reduced Sry messenger RNA, whereas those
with lower GFP gene expression showed modest Sry mRNA
reduction (Figures 2(a) and 2(b)). Since the expression
level of GFP represents expression of shRNA, our results
conﬁrmed that the shRNA could downregulate the Sry
expression eﬃciently. Of note, male embryos with low or no
GFP expression appeared normal (conﬁrmed by histology or
immunostaining) and were excluded from further analysis.
Each group of embryos tested in the study were provide
in Table 1. Western-blot analysis was performed to further
conﬁrm the interfering eﬃciency of shRNA, and the results
showed that in the gonads with high level of GFP expression,
the Sry was signiﬁcantly reduced (Figure 2(c)). Treatment of
the gonads with pSilencer4.1/Sry565 resulted in signiﬁcantly
inhibition of Sry protein expression in male embryos, and
the inhibition rate reached 75% (Figures 2(c) and 2(d))6 Journal of Biomedicine and Biotechnology
compared with the male embryos treated with control plas-
mid,pSilencer4.1/EGFP,ortreatedwith5%glucosesolution.
The results revealed that tail vein injection is an eﬀective
approach to interfering genes expression in developing
embryos.
We next studied the factors aﬀecting the transfection
eﬃciency in developing embryos. In order to study if the
PEI could enhance transfection eﬃciency, 1.0mg pDNA
with or without PEI was delivered into pregnant mice at
9.5dpc, respectively. Embryos were collected at day 11.5,
and the transfection eﬃciency was determined by analyzing
the GFP expression level using microscopy and RT-PCR.
The potential toxic eﬀects of our procedure on animals
were assessed by measurement of mother mouse abortion
rate or dead fetus rate. Our results conﬁrmed that the
transfection rate was signiﬁcantly higher in embryos treated
withpDNA/PEIcomplexthanthattreatedwithnakedpDNA
(Figure 3(a)). Additionally, PEI treatment did not increase
the toxicity (Figure 3(a)). Higher transfection rate could
be obtained when injecting pregnant mice with 0.8mg
pDNA/PEI complex without toxicity (Figure 3(b)). Previous
studies have shown that large volume with rapid injection
usually resulted in a higher level of transgene expression
[12]. We next studied the eﬀect of injection volume and
injectionspeedontransfectioneﬃciency.However,wefound
that large volume with high injection speed always resulted
in stresses, causing pregnant mice abortion; although high
GFP expression was found to be increased in embryos with
increasing injection speed (Figure 3(c)) and large injection
volume (Figure 3(d)),abortionratewasalsoaugmentedwith
increasing the injection speed and volume (Figures 3(c)
and 3(d)). The optimum condition for delivering pDNA
was as follows: 0.8mg of pDNA/PEI with the volume of
1.0mL, injection speed, 10s. Since Sry is only expressed
in a very short period in developing embryos, injection
time is also a critical factor for gene silencing eﬃciency.
We next studied the eﬀects of injection time on the silence
eﬃciency. We delivered 0.8mg of pDNA mixed with proper
amount of PEI into 5 groups of pregnant mice at 5.5, 7.5,
8.5, 9.5, and 10.5dpc, respectively. As shown in Figure 3(e),
the silencing eﬀect of Sry gene is closely related with the
time of pDNA delivery; pDNA delivered in 5.5 and 7.5dpc;
embryos showed very weak GFP expression and embryos
showed modest GFP expression and Sry gene reduction can
be detected in 8.5dpc- and 10.5dpc-treated group. Highly
GFPexpressionandgreatestSry genesilencingwereobserved
in embryos treated at 9.5dpc (Figure 3(e)).
To analyze the eﬀects of reduction expression of Sry
on male gonads development, the gonadal development in
genetic male mice with Sry silencing was assessed by gonadal
histology at 12.5, 13.5, and 15.5dpc, respectively (Figure 4).
Gonadal development in XY-gene-type embryos, treated
with nonsilencing scrambled control shRNA expression
vector (pSilencer4.1/EGFP) with high GFP expression was
developing normally (n = 22) at 12.5, 13.5, and 15.5dpc
(Figures 4(a), 4(d),a n d4(g)), and the XX gene type
female embryo gonads treated with control vectors also
developed normally (Figures 4(c), 4(f),a n d4(i)). Testis
cord could not be visualized in Sry silencing XY embryos
at 12.5dpc (Figure 4(b)). In contrast, the testis cord could
be visualized clearly in the male embryos treated with the
control plasmid (Figure 4(a)). At 13.5dpc, distinct testis
cords could be found in the embryos treated with control
plasmid (Figure 4(d)), whereas no sign of diﬀerentiation was
found in the Sry knockdown male gonads (Figure 4(e)),
with their gonads looking like the female ones (Figure 4(f)).
Similarresultscanalsobeobservedat15.5dpc(Figure 4(h)).
At 15.5dpc, in the control male, the testes cords were
developed completely in embryos untreated (data not show)
or treated with control plasmid (Figure 4(g)), while the Sry
knockdown male gonads showed female-like gonad with
poorly organized cords (Figure 4(h)). These results indicated
that testes development was inhibited in Sry silencing XY
mice fetuses.
TofurtherstudytheeﬀectofSry silenceontheexpression
of sex determination cascade genes, we then checked the
expression of several sex-related genes, including Wt1, Sox9,
Sf1, Amh, Gata4,a n dDax1 at 11.5dpc by Quantitative
RT-PCR in male embryos. Our results showed that the
mRNA levels of Wt1 including Wt1 (−KTS) and Wt1 (+KTS)
were signiﬁcantly increased in Sry silencing embryos gonad
compared to those in the control embryos (Figure 5(a)).
Moreover, the expression level of Sox9 which was thought to
be the most likely target gene of Sry in the Sry cascade was
decreased signiﬁcantly (Figure 5(a)). Western blot analysis
was performed to detect the changes of gene expression in
protein level. As shown in (Figure 5(b)), WT1 (−KTS) and
Wt1 (+KTS) expression levels in Sry knockdown XY gonads
at 11.5dpc were increased. In contrast, the SOX9 expression
level was signiﬁcantly decreased (Figure 5(b)). However, no
obvious change was found for Gata4, Sf1, Amh, and Dax1 in
Sry silencing embryos gonad (Figure 5(a)).
4. Discussion
Over the past years, the speciﬁc gene silencing by RNAi
have made great development. Recently, there were some
reports on silencing postimplantation mouse embryo genes
by RNAi, which oﬀered an opportunity to investigate post-
transcriptional characters of genes in developing embryos
[17, 18, 41]. However, since Sry expression in the developing
embryos only exists in a very short period, very little is
known if it could be knocked-down using RNAi approach.
In the present study, we used a systemic delivery method
to deliver the shRNA expression vector of Sry into the
developingembryosinpregnantmicethroughtailveininjec-
tion. Our study suggested that RNAi would be a powerful
approach to study the function of the temporary expressing
genes in postimplantation-stage developing embryos.
The hydrodynamic injection technique to deliver siRNA
to certain tissues has been used to demonstrate that siRNA-
mediated RNAi could occur in adult mammals [42]. Since
then, several reports have appeared using the technique to
deliver siRNA to various organs in mice and rats. Due to its
easy manipulation and high eﬃciency, the hydrodynamic tail
vein (HTV) injection method has been used for delivery of
nucleic acids to various organs and more successfully to liver.Journal of Biomedicine and Biotechnology 7
25
0
20
15
10
5
PEL (−) PEL (+)
(a)
25
30
0
01 2
20
15
10
5
0.2 0.4 0.8
pDNA mount and transfection rate
(b)
25
0
20
15
10
5
5–10 s
Injection speed and transfection rate
<5 s <30 s >30 s
(c)
25
0
20
15
10
5
30
1 2 0.4 0.2 0.8
Injected volume and transfection rate
(d)
Embryos with high GFP expression rate
Abortion rate
Dead embryo rate
Injected volume and transfection rate
9.5 8.5 7.5 5.5 10.5
25
0
20
15
10
5
(e)
Figure 3: Factors aﬀecting the shRNA deliver eﬃciency and toxicity on developing embryos in vivo. shRNA vector transfection rate was
measured by GFP expression level, and the toxicity was assessed by pregnant mice abortion rate and dead embryo rate. GFP expression
level and dead embryo rate were detected after treatment with plasmids for 48h, and pregnant mice abortion rate was detected at 48h after
injection. (a) Amount of PEI aﬀects pDNA transfection rate and toxicity. 0.8mg of pSilencer4.1/Sry565 plasmid mixed with same amount
of (PEI+) or without PEI (PEI−) diluted in 1.0mL 5% glucose solution was injected into 9.5dpc pregnant mice tail vine in 10 seconds. (b)
Eﬀect of pDNA amount on transfection rate and toxicity. Certain amount of pSilencer4.1/Sry565 plasmids mixed with PEI, diluted in 1.0mL
of 5% glucose solution, were injected into 9.5dpc pregnant mice tail vine in 10 seconds. (c) Eﬀect of injection speed on transfection rate and
toxicity. Pregnant mice at 9.5dpc were intravenously injected with 0.8mg of plasmid DNA and PEI complex in 1.0mL saline. The injection
time was varied from 5 to 30s. (d) Eﬀect of injection volume on transfection rate and toxicity. 0.8mg of plasmid DNA and PEI complex was
diluted in 0.2 to 2.0mL 5% glucose solution and injected into pregnant mice at 9.5dpc. (e) Eﬀects of injection time on transfection rate and
toxicity. 0.8mg of plasmid DNA and PEI complex was diluted 1.0mL 5% glucose solution and injected into pregnant mice various at 5.5dpc
to 10.5dpc. GFP expressions in embryos and dead embryo rate were detected at 11.5dpc. Pregnant mice abortion rate was measured in 48h
after injection.8 Journal of Biomedicine and Biotechnology
XY (pSilencer4.1/EGEP)
12.5 dpc
(a)
XY (pSilencer4.1/Sry565)
(b)
XX (pSilencer4.1/EGEP)
(c)
13.5 dpc
(d) (e) (f)
15.5 dpc
(g) (h)
Bar
(i)
Figure 4: Feminization of male gonads following knock-down of Sry. Starting at 12.5dpc, testis cords (arrows) are visible in the control
plasmid pSilencer4.1-EGFP-treated XY male gonad (a); no signs of diﬀerentiation can be observed in the control females (c) and Sry knock-
down (pSilencer4.1/Sry565 treated) male gonad (b). At 13.5dpc, clearly visible testis cords appeared in control male gonads (d), whereas
in Sry knocked-down male gonad no sign of diﬀerentiation was found (e), just like the control females (f). At 15.5dpc, testis cords can be
observed clearly in control males (g), While unorganized and no visible testis cords were found in Sry knocked-down male embryos’ gonads
(h), developing like the control female gonad (h). The photos were taken at transverse sections; bar = 50μm.
However, there are a lot of factors aﬀecting silencing eﬃ-
ciency in using HTV injection method to deliver shRNA into
embryosthroughmothermouse;severalrelevantparameters
have to be taken into consideration, including (i) siRNA
protection,(ii)transfectioneﬃcacy,(iii)toxicityandabsence
of nonspeciﬁc eﬀects, and (iv) convenient to carry out at
various condition. (v) The ability of the transferring vectors
to overcome numerous biological barriers after systemic
administration to reach their target tissues/organs. In the
present study, we investigated several factors which may
inﬂuence the silence eﬀects. We use a complex of shRNA
expression plasmid and PEI to protect nucleic acid from
nucleasedegradation.Ourresultsshowedthatlowmolecular
weight PEIs were superior for gene transfer in vivo, and a
proper amount of PEI mixed with pDNA is necessary to
enhance transfection eﬃciency and to decrease toxicity. PEIs
for siRNA delivery in vivo have been used in many models
and recently they have been used in clinical therapy for lung
cancer [43]. Our results show that PEIs are a kind of eﬀective
and safe medium for pDNA delivery in transplacental RNAi.
PreviousstudyhasshownthatsystemicdeliveryofpDNA
based on high-pressure, large-volume tail vein injection
could increase transfection eﬃcacy. Our present study also
revealed that large-volume and fast injection enhancesJournal of Biomedicine and Biotechnology 9
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Figure 5: Eﬀects of Sry silencing on gene expression in 11.5dpc male embryo gonads. The value of each gene expression level was divided
to the β-actin expression level in Control males and was normalized as 100%. The two-tail t-test was employed to statistically analyze the
results: ∗∗P<0.01.
the gene transfer eﬃcacy. Since the pregnant mice are
more sensitive to the stresses, extremely large-volume and
too fast injection will cause abortion occurrence. In the
pregnant mice, proper volume and injection speed should be
considered. Previous studies also conﬁrmed that injection
time have great relationship with the transfection eﬃciency;
8.5dpc is the optimum time to deliver plasmid DNA to
developing embryos in mice [44]. It has also been reported
that DNA-liposome complexes were trapped in the visceral
endoderm prior to placenta development on 11.5dpc [45].
Others have also reported hemodynamic transfer of genes
to the fetal compartment. For example, intravenous delivery
of plasmid DNA to pregnant mice on 9.5dpc successfully
immunized the fetuses against HIV-1 and inﬂuenza [46].
Similar results were obtained in the present study; when
delivered pDNA complex with PEI on 5.5, 7.5, 8.5, 9.5, and
10.5dpc, the peak level of pDNA expression was found in
the 9.5dpc delivery group. The results indicated that delivery
pDNA into fetus through pregnant mice at early stage of
embryos development could not get the ideal results as
delivery in the middle development stage.
One drawback using tail vein injection is that plasmid
DNA is likely to be delivered to unintended maternal tissues.
Since the liver has an expandable circulation and is easily
transfected using intravenous delivery, this approach has
been widely used in silencing genes in liver in pregnant
females and neonates. Our present study showed that using
certain volume, and injection speed, no obvious toxicity was
found. Since the function of Sry is sex-related diﬀerentiation
only, its expression in parent tissues does not aﬀect the
development of parent mice. This method would be very
useful to target a gene expressed only in male/female
embryos. The opposite sex litter mates could be served as a
control for maternal eﬀects.
A previous study has shown that Sry is necessary and
suﬃcient for initiating testis determination. In the presence
of Sry, the bipotential gonad anlagen diﬀerentiated into
testes. While in its absence or mutation, the gonad develops
into ovaries or ovotestis. Study using transgenic mice to
knock-out Sry conﬁrmed that XX mouse could develop into
male embryo [19]. Further study revealed that expression
levels of Sry are also important for its function. Sry expres-
sion level has to reach a certain threshold to induce testis
development [37, 40]. Insuﬃcient expression of Sry resulted
in abnormal testis development of XY embryos. In fetuses of
XY Gata4/Fog2 null mutation mice, the Sry transcript levels
were signiﬁcantly reduced and resulted in abnormality in
gonadgenesis. In addition, XY sex reversal was also found
when the Sry expression level reduced to ∼25% of the wild-
type [36]. In the present study, we found that Sry plays a
key role in mouse testis determination. Silencing of Sry in
embryos of genetic male mouse resulted in feminization of
the gonads. Signiﬁcant inhibition of Sox9 expression was
found in Sry-silenced embryos. The results are consistent
withpreviousstudywhichconﬁrmedthatSox9wasregulated
by Sry in gonad. Sox9 was upregulated by the transient
expression of Sry speciﬁcally in Sertoli cell precursors [28].
Our study also revealed that WT1 expression was
increased in Sry knockdown gonads. Wt1 plays an important
role in the initial formation of the undiﬀerentiated genital
ridge and germ cells as well as the spermatogenesis [47, 48].
Inactivation of the mouse Wt1 gene by gene knock out
completely abolishes both renal and gonadal developments
[47, 48]. Studies have shown that Sry expression is in
part regulated by Wt1. During embryogenesis, the Wt1
is initially expressed in intermediate mesoderm at 9.5dpc
before the Sry expression, and Wt1 (−KTS) isoform binds
and transactivates the human and pig Sry promoter in
vitro [34, 49, 50]. However, there was another evidence to
show that in mouse pluripotent conditions of cells, Wt1
expression is regulated by Sry [32] .I nm o u s eE Sc e l ll i n e ,
Sry overexpressionresultedindownregulatedWt1 expression10 Journal of Biomedicine and Biotechnology
[51]. In our present research, silencing Sry in developing
embryos resulted in signiﬁcantly upregulation of WT1,a n d
thisistheﬁrsttimetorevealthatWT1expressionisregulated
by Sry in vivo. It is possible to speculate that there exists
a negative feedback mechanism between Wt1 and Sry. Wt1
might turn on and upregulated Sry expression and high level
expression of Sry downregulates expression of Wt1 to keep
Sry in a suitable level. Study is ongoing in our laboratory
to address if overexpression of WT1 in developing embryo
could result in downregulation of Sry expression.
5. Conclusion
In conclusion, transplacental RNAi can be used to knock-
down of Sry gene during embryo sex diﬀerentiation in devel-
oping mouse embryos. The study revealed that knocking-
down of Sry resulted in feminization of gonad development
in mouse embryos, and the Sox9 and Wt1 genes were
directly regulated by Sry gene. Several factors inﬂuence the
eﬃciency of transplacental RNAi; plasmid complex with
PEI signiﬁcantly enhances the deliver eﬃciency and the
transfection eﬃciency is associated with the amount of
plasmid DNA injection, injection time, injection speed,
and volume. Transplacental RNAi could be implemented
in developing embryos, and this approach provides an
important technique of gene therapy in human sex-linked
diseases.
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